Routine blood count eosinophils may flag recurrence risk in HR-positive breast cancer
A large retrospective analysis links higher circulating eosinophils to fewer recurrences and metastases in HR+/HER2- breast cancer, and to greater CDK4/6 inhibitor benefit.
Summary
Researchers in China found that a number already on every complete blood count, the eosinophil count, may help predict outcomes in the most common type of breast cancer. In a large retrospective analysis of hormone receptor-positive, HER2-negative disease, women with eosinophils above 0.08 x 10^9/L had significantly better recurrence-free survival (P=0.001) and distant metastasis-free survival (P=0.002). Hazard ratios were reduced by roughly 50% to 60%, and the signal held after statistical adjustment. A separate validation cohort showed the same direction of effect, though smaller. Higher counts also tracked with greater benefit from CDK4/6 inhibitors. The authors say eosinophils add information beyond a 21-gene risk score, suggesting they capture an immune dimension the tumor genome misses. This is observational, retrospective work, so it shows association and prediction, not that raising eosinophils would help anyone. It still needs prospective confirmation before it guides treatment.
Detailed Summary
Why this matters: Hormone receptor-positive, HER2-negative breast cancer is the most common breast cancer subtype, and doctors still struggle to tell which women will relapse years later and who gains most from costly add-on drugs such as CDK4/6 inhibitors. A marker that costs almost nothing and is already measured in nearly every patient would be valuable.
Main findings: In a large retrospective analysis from Fudan University Shanghai Cancer Center, published in the Journal of Clinical Oncology, patients with circulating eosinophils above a cutoff of 0.08 x 10^9/L had significantly better recurrence-free survival (P=0.001) and distant metastasis-free survival (P=0.002). Hazard ratio reductions ranged from 50% to 60% before and after adjustment, and eosinophils stayed an independent predictor in multivariable models. A larger validation cohort replicated the direction of the effect, but with smaller hazard ratio reductions. Higher counts also identified patients who benefited more from adjuvant CDK4/6 inhibitor therapy.
Key insights: The eosinophil count added prognostic value beyond the 21-gene risk score, implying that blood immune status captures biology distinct from tumor genomics. Earlier work linked higher lymphocyte counts and lower neutrophil-to-lymphocyte ratios to better outcomes, mainly in HR-negative disease. An accompanying editorial noted that none of these inexpensive blood markers is in routine use.
Practical implications: For now this is not a reason to act on your own blood count. It signals that a standard complete blood count may eventually help refine recurrence risk and drug selection. Women in treatment can ask their oncologist how immune markers fit into their care.
Caveats: The design is retrospective and observational, so it shows association, not cause. The effect size differed between discovery and validation cohorts. The cutoff needs prospective testing, and the article does not detail the biological mechanism, cohort sizes, or other factors such as medications that can alter eosinophils.
Key Findings
- Eosinophils above 0.08 x 10^9/L linked to better recurrence-free (P=0.001) and distant metastasis-free survival (P=0.002) in HR+ breast cancer.
- Hazard ratio reductions were 50-60% and remained significant after multivariable adjustment.
- A larger validation cohort replicated the protective direction, with smaller hazard ratio reductions.
- Higher eosinophil counts predicted greater benefit from adjuvant CDK4/6 inhibitors.
- Eosinophils added prognostic value beyond the 21-gene risk score, suggesting an independent immune signal.
Methodology
This is a news report in MedPage Today on a retrospective cohort analysis with a validation cohort, published in the Journal of Clinical Oncology by Fudan University researchers, with an accompanying editorial. The evidence is observational and prognostic or predictive, and the endpoints are recurrence-free and distant metastasis-free survival. The excerpt gives no cohort sizes and no biological mechanism.
Study Limitations
The study is retrospective, so confounding is possible, and effect sizes differed between the discovery and validation cohorts. The excerpt omits sample sizes, absolute risk differences, and how eosinophils might exert an effect. Check the primary paper for cohort details, the predictive interaction data, and whether the cutoff holds in other populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
